Allogene Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Allogene Therapeutics, Inc. (ALLO) had Debt Securities, Available-for-sale, Amortized Cost of $419.68 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $419.68M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $261.81M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $254.87M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $270.69M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $419.68M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $261.81M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $254.87M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $270.69M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $301.13M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $331.19M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $368.79M 10-K · filed 2026-03-12 |
| 2024-09-30 | $395.52M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $435.84M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $391.73M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $444.59M 10-K · filed 2025-03-13 |
| 2023-09-30 | $491.31M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $541.59M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $512.88M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $535.81M 10-K/A · filed 2024-03-14 |
| 2022-09-30 | $594.72M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $633.96M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $692.75M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $754.16M 10-K/A · filed 2024-03-14 |
| 2021-09-30 | $806.45M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $859.35M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $903.58M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $950.10M 10-K · filed 2022-02-23 |
| 2020-09-30 | $990.55M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $1.08B 10-Q · filed 2020-08-05 |
| 2020-03-31 | $537.24M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $535.04M 10-K · filed 2021-02-25 |
| 2019-09-30 | $551.19M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $580.21M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $607.37M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $713.71M 10-K · filed 2020-02-27 |
| 2018-09-30 | $394.94M 10-Q · filed 2018-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |